Kerecis, a company developing a tissue-regeneration material derived from fish skin to accelerate the healing of wounds and tissue reconstruction, has secured $2 million in Series A3 funding, with participation from all existing investors, as well as two new investors. The capital will be used to further develop MariGen Omega3, the company's tissue-regeneration technology.
MariGen Omega3 is fish skin that has had all its cells and antigenic materials removed; it is applied to areas of tissue damage where it recruits the body's own cells and ultimately converts into functional, living tissue. The product is available for sale in Iceland, the U.K. and several Middle Eastern markets. With Kerecis receiving a U.S. patent for the technology last December, and being close to receiving patents in several other countries, it will soon expand distribution to new markets.